FY25 saw lower sales due to program delays, but a strong capital raise and strategic alliances position the company for FY26 growth. Expansion into public screening programs and new markets, along with product diversification, are expected to drive revenue and reduce reliance on China.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.